Insulin pump therapy is perceived as liberating, but to many it can imply a sense of the diabetes made visible

European Diabetes Nursing

Volumn 11, Issue 2, 2014, Pages 38-42

  Saarinen, Tuula ^a   Fernström, Lillemor ^b   Brorsson, Anna Lena ^c   Olinder, Anna Lindholm ^c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Breast Association   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus type 1; Insulin infusion system; Qualitative research; Quality of life; Treatment satisfaction

Indexed keywords

EID: 84905453502     PISSN: 15517853     EISSN: 15517861     Source Type: Journal    
DOI: 10.1002/edn.246     Document Type: Article

References (16)

1. The Swedish National Diabetes Registry. NDR report 2011. (https://www.ndr.nu/; accessed 16 June 2014).
2. De Vries JH, Snoek FJ, Kostense PJ, et al. A randomised trial of continuous subcutaneous insulin infusion system and intensive injection therapy in type 1 diabetes for patients with longstanding poor glycemic control. Diabetes Care 2002;25:2074-2080.
3. Bruttomesso D, Crazzolara D, Maran A, et al. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabetic Medicine 2008; 25:326-332.
4. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Medicine 2005;23:141-147.
5. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Medicine 2002;19:746-751.
6. Misso ML, Egbets KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus (Review): The Cochrane collaboration 2010;1:CD005103.
7. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1-6.
8. Garmo A, Garmo H, Ärnlöv J, Leksell J. Long-term treatment effects of insulin pump therapy. Practical Diabetes 2011; 28:295-299.
9. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro. Diabetes Care 2001;24:1722-1727.
10. Barnard KD, Skinner TC. Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Practical Diabetes 2007;24:143-148.
11. Garmo A, Hornsten A, Leksell J. "The pump was a savior for me". Patient′s experiences of insulin pump therapy. Diabetic Medicine 2013;30:717-723.
12. Ritholtz MD, Smaldone A, Lee J, et al. Perceptions of psychosocial factors and the insulin pump. Diabetes Care 2007; 30:549-554.
13. Todres L, Keen S, Kerr D. Continuous subcutaneous insulin infusion in type 1 diabetes: patient experiences of "living with a machine". Diabetic Medicine 2010; 27:1201-1204.
14. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Education Today 2004;24:105-112.
15. Scheidegger U, Allemann S, Scheidegger K, Diem P. Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Medical Weekly 2007; 137:476-482.
16. Bolli G, Kerr D, Reena T, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes. Diabetes Care 2009; 32:1170-1176.